rifampin vs. rifapentine: a debate over the preferred rifamycin | kelly dooley, md, phd
Published 3 years ago • 607 plays • Length 13:36Download video MP4
Download video MP3
Similar videos
-
8:58
rifampin vs. rifapentine: a debate over the preferred rifamycin | charles peloquin, pharmd
-
25:28
lessons learned for future tb drug development: a review of rifapentine - kelly elise dooley
-
24:55
controversies in tb meningitis | kelly dooley, md, phd
-
6:11
ifcc clinical case 18：a case of “pulmonary isolated infection” by tropheryma whipplei in a six year
-
1:46
r-chop versus r-bendamustine in fl
-
20:52
what’s new in the treatment of rifampin resistant tb - francesca conradie, mbbch
-
1:30:48
inh and rifapentine treatment for ltbi
-
1:06:23
rnl 2021: keynote and global rheumatology registry update - drs. iain mcinnes and philip robinson
-
16:05
discussing ra: neutrophil-to-lymphocyte ratio and treatment response to filgotinib
-
1:56:44
fight against pneumonia - what is new?
-
7:58
a multidrug-resistant tb patient's story
-
1:23
antibiotic prediction solution made by students
-
8:27
rifampin
-
6:47
cd14 monocytes and ra – implications for practice and research
-
29:37
instis use in tuberculosis co-infection - graeme meintjes, mbchb, frcp, fcp, diphivman, mph, phd
-
15:10
dr parzmair presents rct data for vpm1002 - a recombinant bcg (rbcg) vaccine - against covid-19.
-
2:04
preliminary results from the blin01 trial
-
1:57
rt pcr: the best test for covid-19?
-
25:00
role of clinical pharmacology in management of hiv tb co-infections - tim cressey, phd
-
1:01:34
1/11/22 medicine grand rounds - dr. patrawalla
-
7:32
discussing rheumatology: tofacitinib safety and dose-switching in ra
-
24:14
antimicrobial optimisation - antimycobacterial dosing & therapeutic drug monitoring - prof alffenaar